Clinical Trial

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 29, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Protocol Amendment History 3 changes
notable Enrollment increased: 36 -> 58 participants 2026-06-30
notable Primary completion pushed: 2026-06 -> 2026-07 2026-06-30
critical Recruitment opened 2026-04-18
Trial Details
NCT Number NCT07479641
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Cardiomyopathy
Enrollment 58 participants
Start Date 2026-04-14
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-29